AstraZeneca Q3 EPS Estimate Decreased by Leerink Partnrs

AstraZeneca PLC (NASDAQ:AZN - Free Report) - Research analysts at Leerink Partnrs cut their Q3 2024 EPS estimates for AstraZeneca in a note issued to investors on Monday, October 28th. Leerink Partnrs analyst A. Berens now forecasts that the company will post earnings of $1.02 per share for the quarter, down from their prior forecast of $1.09. The consensus estimate for AstraZeneca's current full-year earnings is $4.07 per share. Leerink Partnrs also issued estimates for AstraZeneca's FY2024 earnings at $4.10 EPS.

Other equities analysts have also issued research reports about the stock. TD Cowen upped their price target on shares of AstraZeneca from $90.00 to $95.00 and gave the stock a "buy" rating in a research report on Monday, August 12th. Erste Group Bank raised shares of AstraZeneca from a "hold" rating to a "buy" rating in a research report on Wednesday, September 11th. Finally, Deutsche Bank Aktiengesellschaft lowered shares of AstraZeneca from a "hold" rating to a "sell" rating in a research report on Friday, September 13th. One analyst has rated the stock with a sell rating, one has issued a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $89.75.

AstraZeneca Trading Down 3.2 %

Shares of NASDAQ:AZN traded down $2.39 during trading on Wednesday, reaching $72.83. The stock had a trading volume of 8,228,650 shares, compared to its average volume of 5,013,994. The business has a fifty day moving average price of $80.03 and a 200-day moving average price of $78.68. The company has a quick ratio of 0.69, a current ratio of 0.89 and a debt-to-equity ratio of 0.69. The stock has a market cap of $225.82 billion, a P/E ratio of 36.34, a PEG ratio of 1.39 and a beta of 0.46. AstraZeneca has a fifty-two week low of $60.47 and a fifty-two week high of $87.68.

Institutional Investors Weigh In On AstraZeneca

Several institutional investors have recently bought and sold shares of the business. McClarren Financial Advisors Inc. boosted its stake in shares of AstraZeneca by 320.8% in the third quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company's stock valued at $25,000 after purchasing an additional 247 shares during the period. GHP Investment Advisors Inc. purchased a new position in shares of AstraZeneca in the second quarter valued at $26,000. Pathway Financial Advisers LLC purchased a new position in shares of AstraZeneca in the first quarter valued at $29,000. RFP Financial Group LLC boosted its stake in shares of AstraZeneca by 56.3% in the first quarter. RFP Financial Group LLC now owns 494 shares of the company's stock valued at $33,000 after purchasing an additional 178 shares during the period. Finally, CANADA LIFE ASSURANCE Co boosted its stake in shares of AstraZeneca by 40.6% in the first quarter. CANADA LIFE ASSURANCE Co now owns 506 shares of the company's stock valued at $34,000 after purchasing an additional 146 shares during the period. 20.35% of the stock is currently owned by hedge funds and other institutional investors.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.